Ranolazine-tacrolimus interaction

Annals of Pharmacotherapy

Volumn 44, Issue 11, 2010, Pages 1844-1849

  Pierce, Dwayne A ^a   Reeves Daniel, Amber M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

CYP3A; Drug interaction; P glycoprotein; Ranolazine; Tacrolimus

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; BICARBONATE; COTRIMOXAZOLE; CYTOCHROME P450 3A; FLUCONAZOLE; GLIPIZIDE; GLYCERYL TRINITRATE; GLYCOPROTEIN P; HYDRALAZINE; IMMUNOGLOBULIN; IRON SACCHARATE; ISOSORBIDE MONONITRATE; LOSARTAN; MAGNESIUM OXIDE; METHYLPREDNISOLONE; METOPROLOL SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; POLYSTYRENESULFONATE SODIUM; PREDNISONE; RANOLAZINE; SIMVASTATIN; TACROLIMUS;

ADULT; AFRICAN AMERICAN; ANGINA PECTORIS; ARTICLE; CASE REPORT; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INHIBITION; FEMALE; FIRST PASS EFFECT; HUMAN; HYPERTENSION; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ACETANILIDES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; P-GLYCOPROTEIN; PIPERAZINES; TACROLIMUS;

EID: 78049475850     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P297     Document Type: Article

References (23)

1. Product information. Ranexa (ranolazine). Palo Alto, CA: CV Therapeutics, Inc., March 2009.
2. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet 2006;45:469-91.
3. Product information. Prograf (tacrolimus). Deerfield, IL: Fujisawa Healthcare, Inc., August 2009.
4. Staatz C, Tett S. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004;43:623-53.
5. Jerling M, Abdallah H. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther 2005;78:288-97. DOI 10.1016/j.clpt.2005.05.004
6. McCormack J, Stanley W, Wolff A. Ranolazine: a novel metabolic modulator for the treatment of angina. Gen Pharmacol 1998;30:639-45.
7. Chaitman B. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006;113:2462-72. DOI 10.1161/CIRCULATIONAHA.105.597500
8. Wandel C, Kim R, Kajiji S, Gueugerich P, Wilkinson G, Wood A. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999;59:3944-8.
9. Steeves M, Abdallah H, Venkataramanan R, et al. In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. J Pharm Pharmacol 1991;43:574-7.
10. Utecht K, Hiles J, Kolesar J. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am J Health Syst Pharm 2006;63:2340-8. DOI 10.2146/ajhp060080
11. Jones T, Morris R. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet 2002;41:381-8.
12. Saad A, DePestel D, Carver P. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26:1730-44.
13. Burger C, Clase C, Gangji A. Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. Transplantation 2010; 89:1166-7. DOI 10.1097/TP.0b13e318d2fed7
14. Capone D, Tarantino G, Gentile A, et al. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. J Clin Pharm Ther 2010;35:121-4. DOI 10.111/j.1365-2710.2009.01070.x
15. Hansten P, Horn J. Drug interactions analysis and management. St. Louis, MO: Facts and Comparisons Publishing Group, Wolters Kluwer Health, April 2010: PM1-16.
16. Saeki T, Tanigawara Y, Komano T. Human P-glycoprotein transports cyclosporine A and FK 506. J Biol Chem 1993;268:6077-80.
17. Thummell K, Shen D, Isoherranen N. Role of the gut mucosa in metabolically based drug interactions. In: Rodrigues AD, ed. Drug-drug interactions, 2nd ed. New York: Informa Healthcare, 2008:471-81.
18. Lemahieu W, Maes B, Verbeke K, Vanrenterghem Y. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation. Kidney Int 2005;67:1152-60.
19. Pauli-Magnus C, Rekersbrink UK, Fromm M. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Nauyn Schmiedebergs Arch Pharmacol 2001;364:551-7.
20. Schwerer H, Lorf T, Ringe B, Ramadori G. Pantoprazole and cyclosporin or tacrolimus. Aliment Pharmacol Ther 2001;15:559-62.
21. Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996;124:316-20.
22. Product information. Cozaar (losartan).Whitehouse Station, NJ: Merck and Company, Inc., December 2009.
23. Horn J, Hansten P, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;47:674-80. DOI 10.1345/aph.1H423